Revier Therapeutics
Advancing disease-modifying therapies for patients with cardiometabolic disease
Biotechnology Research·0 Followers
Overview
Revier has established the first therapeutic approach to selectively target class IIa HDACs to treat cardiometabolic diseases. Our orally available small molecules are designed to inhibit the pathogenic enzymatic activity while preserving healthy biological function and avoiding canonical HDAC inhibition. We are advancing a pipeline of novel disease modulators starting with heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD) as our initial in...See more
Website
https://revier.bio/Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Heidelberg
Upgrade to view team
View current team members and their roles
Access founders information
Request warm introductions
Funding Rounds (1)
EUR 6,000,000 • Seed
Announced on 8/25/2026
Open Positions(0)
No open jobs posted for this organization yet.
Company Updates
No updates available yet.